NYSE:NVS - Novartis Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $87.33 -0.98 (-1.11 %) (As of 11/14/2018 04:00 PM ET)Previous Close$88.31Today's Range$87.15 - $88.3252-Week Range$72.30 - $94.19Volume2.29 million shsAverage Volume1.90 million shsMarket Capitalization$204.47 billionP/E Ratio18.16Dividend Yield2.16%Beta0.73 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; and Conatus Pharmaceuticals Inc. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland. Receive NVS News and Ratings via Email Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVS Previous Symbol CUSIPN/A Webwww.novartis.com Phone41-61-324-1111 Debt Debt-to-Equity Ratio0.29 Current Ratio1.20 Quick Ratio0.96 Price-To-Earnings Trailing P/E Ratio18.16 Forward P/E Ratio16.89 P/E Growth1.95 Sales & Book Value Annual Sales$49.11 billion Price / Sales4.12 Cash Flow$7.4577 per share Price / Cash11.71 Book Value$33.67 per share Price / Book2.59 Profitability EPS (Most Recent Fiscal Year)$4.81 Net Income$7.70 billion Net Margins25.98% Return on Equity15.81% Return on Assets8.58% Miscellaneous Employees121,597 Outstanding Shares2,317,460,000Market Cap$204.47 billion OptionableOptionable Novartis (NYSE:NVS) Frequently Asked Questions What is Novartis' stock symbol? Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS." How will Novartis' stock buyback program work? Novartis declared that its board has authorized a stock repurchase program on Saturday, April 8th 2017, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 2.9% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's board of directors believes its stock is undervalued. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) announced its quarterly earnings results on Thursday, October, 18th. The company reported $1.32 EPS for the quarter, beating the Zacks' consensus estimate of $1.31 by $0.01. The company had revenue of $12.78 billion for the quarter, compared to analyst estimates of $12.88 billion. Novartis had a return on equity of 15.81% and a net margin of 25.98%. The firm's revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.29 EPS. View Novartis' Earnings History. When is Novartis' next earnings date? Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, January 23rd 2019. View Earnings Estimates for Novartis. What price target have analysts set for NVS? 15 brokers have issued 12-month price objectives for Novartis' stock. Their predictions range from $74.71 to $74.71. On average, they expect Novartis' share price to reach $74.71 in the next twelve months. This suggests that the stock has a possible downside of 14.5%. View Analyst Price Targets for Novartis. What is the consensus analysts' recommendation for Novartis? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 11 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis. Has Novartis been receiving favorable news coverage? Headlines about NVS stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novartis earned a coverage optimism score of 1.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. Are investors shorting Novartis? Novartis saw a increase in short interest in October. As of October 31st, there was short interest totalling 4,932,071 shares, an increase of 109.0% from the October 15th total of 2,360,402 shares. Based on an average daily volume of 3,830,632 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.2% of the company's stock are sold short. View Novartis' Current Options Chain. Who are some of Novartis' key competitors? Some companies that are related to Novartis include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), Novo Nordisk A/S (NVO), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG), Allergan (AGN) and Celgene (CELG). Who are Novartis' key executives? Novartis' management team includes the folowing people: Dr. Vasant Narasimhan, Chief Exec. Officer (Age 42)Mr. Harry Kirsch, Chief Financial Officer (Age 53)Mr. Steven Baert, Head of HR (Age 44)Mr. Richard Francis, Chief Exec. Officer of Sandoz (Age 50)Dr. James E. Bradner M.D., Pres of Novartis Institutes for Biomedical Research (Age 46) Who are Novartis' major shareholders? Novartis' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (0.96%), Franklin Resources Inc. (0.65%), Fisher Asset Management LLC (0.32%), Loomis Sayles & Co. L P (0.32%), BlackRock Inc. (0.15%) and Manning & Napier Group LLC (0.15%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis. Which institutional investors are selling Novartis stock? NVS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Franklin Resources Inc., Deutsche Bank AG, BlackRock Inc., Manning & Napier Group LLC, Sei Investments Co., Capital Fund Management S.A. and JPMorgan Chase & Co.. View Insider Buying and Selling for Novartis. Which institutional investors are buying Novartis stock? NVS stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Janus Henderson Group PLC, Bank of New York Mellon Corp, Rockefeller Capital Management L.P., The Manufacturers Life Insurance Company , Allianz Asset Management GmbH, Connor Clark & Lunn Investment Management Ltd. and Loomis Sayles & Co. L P. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis. How do I buy shares of Novartis? Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Novartis' stock price today? One share of NVS stock can currently be purchased for approximately $87.33. How big of a company is Novartis? Novartis has a market capitalization of $204.47 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $4.81 on an earnings per share basis. Novartis employs 121,597 workers across the globe. What is Novartis' official website? The official website for Novartis is http://www.novartis.com. How can I contact Novartis? Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected] MarketBeat Community Rating for Novartis (NYSE NVS)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 400 (Vote Outperform)Underperform Votes: 472 (Vote Underperform)Total Votes: 872MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/14/2018 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?